SCHEMBL6156705

SCHEMBL6156705

CN1CCN(C(=O)OCCC2CCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 15/20 0.53
HPGD P15428 1/20 0.46
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6402850 0.95 GPR119 (0.51) GPR119HPGD
SCHEMBL6156540 0.90 GPR119 (0.53) GPR119HPGDKDM4EPKM
SCHEMBL6156324 0.89 HPGD (0.58) GPR119HPGDKDM4EPKM
SCHEMBL6150245 0.87 GPR119 (0.51) GPR119HPGDKDM4EPKM
SCHEMBL6155301 0.87 HPGD (0.47) GPR119HPGDKDM4EPKM
SCHEMBL5192061 0.85 GPR119 (0.51) GPR119HPGDKDM4EPKM
SCHEMBL5192065 0.84 KDM4E (0.51) GPR119HPGDKDM4EPKM
SCHEMBL8423975 0.84 GPR119 (0.50) GPR119HPGDKDM4EPKM
SCHEMBL19562153 0.84 ALDH1A1 (0.46) KDM4E
SCHEMBL4096002 0.83 GPR119 (0.50) GPR119HPGDKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143391-A1 Heterocyclic amides with alpha-4 integrin antagonist activity J. Uriach Y Compañia S.A. (ES) 2005-06-30 US disclosed
EP-1495044-A1 HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY J. Uriach y Compania S.A. (ES) 2005-01-12 EP disclosed
WO-2003084984-A1 HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY J. URIACH Y COMPANIA S.A. (ES) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143391-A1 Heterocyclic amides with alpha-4 integrin antagonist activity ITGB4, ITGA4, ITGA1 GPR119 789/4885HPGD 1642/4885KDM4E 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.